Minerva Surgical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 09, 2022 at 05:17 pm EDT
Share
Minerva Surgical, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 12.97 million compared to USD 14.11 million a year ago. Net loss was USD 5.61 million compared to USD 14.1 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 5.48 a year ago.
For the six months, sales was USD 23.9 million compared to USD 25.95 million a year ago. Net loss was USD 16.54 million compared to USD 29.05 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 15.49 a year ago.
Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. It has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. It offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.
MINERVA SURGICAL, INC. 
